INCYTE CORPORATION Excess Tax Benefit from Share-based Compensation, Financing Activities
INCYTE CORPORATION (INCY) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $3.83 million for the 3-month period ending 2015-03-31, per its 10-Q filed 2015-04-30.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2015-04-30
- INCYTE CORPORATION excess tax benefit from share-based compensation, financing activities for the quarter ending 2015-03-31 was $3.83M.
- INCYTE CORPORATION excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-12-31 was -$96.00K.
- INCYTE CORPORATION excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-09-30 was $105.00K.
- INCYTE CORPORATION excess tax benefit from share-based compensation, financing activities for the quarter ending 2014-06-30 was $0.00.
- INCYTE CORPORATION excess tax benefit from share-based compensation, financing activities for fiscal 2014 was -$22.00K, a 110.28% decline from fiscal 2013.
- INCYTE CORPORATION excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $214.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month |
|---|---|---|---|---|
| 2015-03-31 | $3.83M 10-Q · filed 2015-04-30 | $3.74M derived: sum of 2 quarters · filed 2015-04-30 | $3.84M derived: sum of 3 quarters · filed 2015-04-30 | $3.84M derived: sum of 4 quarters · filed 2015-04-30 |
| 2014-12-31 | -$96.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-17 | $9.00K derived: sum of 2 quarters · filed 2015-02-17 | $9.00K derived: sum of 3 quarters · filed 2015-02-17 | -$22.00K 10-K · filed 2015-02-17 |
| 2014-09-30 | $105.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $105.00K derived: sum of 2 quarters · filed 2014-10-30 | $74.00K 10-Q · filed 2014-10-30 | |
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-31 | -$31.00K 10-Q · filed 2014-07-31 | ||
| 2014-03-31 | -$31.00K 10-Q · filed 2015-04-30 | |||
| 2013-12-31 | $214.00K 10-K · filed 2015-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| IQVIA HOLDINGS INC. (IQV) | United States | $45.926B | 20.54 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |